Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 73.50
+1.20 (1.66%)
May 7, 2026, 4:08 PM HKT
Keymed Biosciences Market Cap
Keymed Biosciences has a market cap or net worth of 21.65 billion as of May 7, 2026. Its market cap has increased by 79.17% in one year.
Market Cap
21.65B
Enterprise Value
20.39B
Revenue
797.12M
Ranking
n/a
PE Ratio
n/a
Stock Price
73.50
Market Cap Chart
Since July 8, 2021, Keymed Biosciences's market cap has increased from 18.43B to 21.65B, an increase of 17.50%. That is a compound annual growth rate of 3.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 7, 2026 | 21.65B | 37.51% |
| Dec 31, 2025 | 15.75B | 84.90% |
| Dec 31, 2024 | 8.52B | -37.32% |
| Dec 29, 2023 | 13.59B | -4.15% |
| Dec 30, 2022 | 14.17B | 46.87% |
| Dec 31, 2021 | 9.65B | -47.63% |
| Jul 8, 2021 | 18.43B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genscript Biotech | 31.53B |
| InnoCare Pharma | 27.39B |
| Duality Biotherapeutics | 23.08B |
| TransThera Sciences (Nanjing) | 19.62B |
| Zai Lab | 18.50B |
| Ascletis Pharma | 17.51B |
| Ascentage Pharma Group International | 16.11B |
| Nanjing Leads Biolabs | 15.67B |